The above results indicate that the first-line treatment of PD-L1-negative advanced NSCLC with cadonilimab in combination with chemotherapy shows an auspicious therapeutic effect, especially in patients with squamous carcinoma. The gene discussed is CD274; the disease is non-small cell lung carcinoma.